Jan 14, 2016

Progress and prospects for blood-stage malaria vaccines

Expert Review of Vaccines
Kazutoyo Miura

Abstract

There have been significant decreases in malaria mortality and morbidity in the last 10-15 years, and the most advanced pre-erythrocytic malaria vaccine, RTS,S, received a positive opinion from European regulators in July 2015. However, no blood-stage vaccine has reached a phase III trial. The first part of this review summarizes the pros and cons of various assays and models that have been and will be used to predict the efficacy of blood-stage vaccines. In the second part, blood-stage vaccine candidates that showed some efficacy in human clinical trials or controlled human malaria infection models are discussed. Then, candidates under clinical investigation are described in the third part, and other novel candidates and strategies are reviewed in the last part.

Mentioned in this Paper

Morbidity Aspects
Phase 3 Clinical Trials
Strategy
Vaccines
Encephalomyelitis, Acute Disseminated
Vaccination
Malaria
Malaria Vaccines
Clinical Trials
Congenital Malaria

Related Feeds

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Related Papers

BMJ : British Medical Journal
Christopher J A Duncan, Adrian V S Hill
The Lancet Infectious Diseases
Alassane Dicko, Ogobara K Doumbo
Medical and Pediatric Oncology
O B Eden
BMJ : British Medical Journal
Christopher J M Whitty
© 2020 Meta ULC. All rights reserved